{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1360565166137237760.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1016/j.tranon.2017.07.004"}},{"identifier":{"@type":"URI","@value":"https://api.elsevier.com/content/article/PII:S1936523317301523?httpAccept=text/xml"}},{"identifier":{"@type":"URI","@value":"https://api.elsevier.com/content/article/PII:S1936523317301523?httpAccept=text/plain"}},{"identifier":{"@type":"PMID","@value":"28778025"}}],"resourceType":"学術雑誌論文(journal article)","dc:title":[{"@value":"Comparison of ESR1 Mutations in Tumor Tissue and Matched Plasma Samples from Metastatic Breast Cancer Patients"}],"description":[{"notation":[{"@value":"ESR1 mutation in circulating cell-free DNA (cfDNA) is emerging as a noninvasive biomarker of acquired resistance to endocrine therapy, but there is a paucity of data comparing the status of ESR1 gene in cfDNA with that in its corresponding tumor tissue. The objective of this study is to validate the degree of concordance of ESR1 mutations between plasma and tumor tissue.ESR1 ligand-binding domain mutations Y537S, Y537N, Y537C, and D538G were analyzed using droplet digital PCR in 35 patients with metastatic breast cancer (MBC) (35 tumor tissue samples and 67 plasma samples).Of the 35 paired samples, 26 (74.3%) were concordant: one patient had detectable ESR1 mutations both plasma (ESR1 Y537S/Y537N) and tumor tissue (ESR1 Y537S/Y537C), and 25 had WT ESR1 alleles in both. Nine (25.7%) had discordance between the plasma and tissue results: five had mutations detected only in their tumor tissue (two Y537S, one Y537C, one D538G, and one Y537S/Y537N/D538G), and four had mutations detected only in their plasma (one Y537S, one Y537N, and two Y537S/Y537N/D538G). Furthermore, longitudinal plasma samples from 19 patients were used to assess changes in the presence of ESR1 mutations during treatment. Eleven patients had cfDNA ESR1 mutations over the course of treatment. A total of eight of 11 patients with MBC with cfDNA ESR1 mutations (72.7%) had the polyclonal mutations.We have shown the independent distribution of ESR1 mutations between plasma and tumor tissue in 35 patients with MBC."}]}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1420282801199857408","@type":"Researcher","personIdentifier":[{"@type":"KAKEN_RESEARCHERS","@value":"60736289"},{"@type":"NRID","@value":"1000060736289"},{"@type":"NRID","@value":"9000411377995"},{"@type":"NRID","@value":"9000259322320"},{"@type":"NRID","@value":"9000370754775"},{"@type":"RESEARCHMAP","@value":"https://researchmap.jp/7000016941"}],"foaf:name":[{"@value":"Takashi Takeshita"}]},{"@id":"https://cir.nii.ac.jp/crid/1380284919340270849","@type":"Researcher","foaf:name":[{"@value":"Yutaka Yamamoto"}]},{"@id":"https://cir.nii.ac.jp/crid/1380284919340270851","@type":"Researcher","foaf:name":[{"@value":"Mutsuko Yamamoto-Ibusuki"}]},{"@id":"https://cir.nii.ac.jp/crid/1420564276183361792","@type":"Researcher","personIdentifier":[{"@type":"KAKEN_RESEARCHERS","@value":"20794457"},{"@type":"NRID","@value":"1000020794457"},{"@type":"NRID","@value":"9000242825650"},{"@type":"NRID","@value":"9000018669834"},{"@type":"NRID","@value":"9000237611753"},{"@type":"RESEARCHMAP","@value":"https://researchmap.jp/7000021391"}],"foaf:name":[{"@value":"Mai Tomiguchi"}]},{"@id":"https://cir.nii.ac.jp/crid/1380284919340270848","@type":"Researcher","foaf:name":[{"@value":"Aiko Sueta"}]},{"@id":"https://cir.nii.ac.jp/crid/1030848083469900672","@type":"Researcher","personIdentifier":[{"@type":"KAKEN_RESEARCHERS","@value":"20530124"},{"@type":"NRID","@value":"1000020530124"},{"@type":"NRID","@value":"9000002888053"},{"@type":"NRID","@value":"9000018292256"},{"@type":"NRID","@value":"9000009540633"},{"@type":"NRID","@value":"9000008355603"},{"@type":"NRID","@value":"9000237617941"},{"@type":"NRID","@value":"9000237603636"},{"@type":"NRID","@value":"9000283330616"},{"@type":"NRID","@value":"9000255861826"},{"@type":"NRID","@value":"9000408608079"}],"foaf:name":[{"@value":"Keiichi Murakami"}]},{"@id":"https://cir.nii.ac.jp/crid/1380284919340270720","@type":"Researcher","foaf:name":[{"@value":"Yoko Omoto"}]},{"@id":"https://cir.nii.ac.jp/crid/1380284919340270723","@type":"Researcher","foaf:name":[{"@value":"Hirotaka Iwase"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"19365233"}],"prism:publicationName":[{"@value":"Translational Oncology"}],"dc:publisher":[{"@value":"Elsevier BV"}],"prism:publicationDate":"2017-10","prism:volume":"10","prism:number":"5","prism:startingPage":"766","prism:endingPage":"771"},"reviewed":"false","dc:rights":["https://www.elsevier.com/tdm/userlicense/1.0/","https://www.elsevier.com/legal/tdmrep-license","http://creativecommons.org/licenses/by-nc-nd/4.0/"],"url":[{"@id":"https://api.elsevier.com/content/article/PII:S1936523317301523?httpAccept=text/xml"},{"@id":"https://api.elsevier.com/content/article/PII:S1936523317301523?httpAccept=text/plain"}],"createdAt":"2017-08-01","modifiedAt":"2025-10-30","foaf:topic":[{"@id":"https://cir.nii.ac.jp/all?q=Original%20article","dc:title":"Original article"},{"@id":"https://cir.nii.ac.jp/all?q=Neoplasms.%20Tumors.%20Oncology.%20Including%20cancer%20and%20carcinogens","dc:title":"Neoplasms. Tumors. Oncology. Including cancer and carcinogens"},{"@id":"https://cir.nii.ac.jp/all?q=RC254-282","dc:title":"RC254-282"}],"project":[{"@id":"https://cir.nii.ac.jp/crid/1040000781852100352","@type":"Project","projectIdentifier":[{"@type":"KAKEN","@value":"15K10057"},{"@type":"JGN","@value":"JP15K10057"},{"@type":"URI","@value":"https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-15K10057/"}],"notation":[{"@language":"ja","@value":"転移乳癌に対するエストロゲン付加療法のメカニズム解析"},{"@language":"en","@value":"Mechanism analysis of estrogen addition therapy for metastatic breast cancer"}]},{"@id":"https://cir.nii.ac.jp/crid/1040282256950027008","@type":"Project","projectIdentifier":[{"@type":"KAKEN","@value":"17K16511"},{"@type":"JGN","@value":"JP17K16511"},{"@type":"URI","@value":"https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-17K16511/"}],"notation":[{"@language":"ja","@value":"乳癌におけるリキッドバイオプシー法の開発と臨床応用への取り組み"},{"@language":"en","@value":"Development of liquid biopsy method for breast cancer clinical application."}]}],"relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1360011144203051264","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Breast Cancer Version 3.2014"}]},{"@id":"https://cir.nii.ac.jp/crid/1360011144793417600","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"ESR1 ligand-binding domain mutations in hormone-resistant breast cancer"}]},{"@id":"https://cir.nii.ac.jp/crid/1360011145759597952","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Liquid Biopsies: Genotyping Circulating Tumor DNA"}]},{"@id":"https://cir.nii.ac.jp/crid/1360285705462486272","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"dPCR Mutational Analyses in Cell-Free DNA: A Comparison with Tissues"}]},{"@id":"https://cir.nii.ac.jp/crid/1360292620480824960","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Sensitive Detection of Mono- and Polyclonal ESR1 Mutations in Primary Tumors, Metastatic Lesions, and Cell-Free DNA of Breast Cancer Patients"}]},{"@id":"https://cir.nii.ac.jp/crid/1360565166140031616","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Droplet digital polymerase chain reaction assay for screening of ESR1 mutations in 325 breast cancer specimens"}]},{"@id":"https://cir.nii.ac.jp/crid/1360565169869046016","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Clinical significance of monitoring <i>ESR1</i> mutations in circulating cell-free DNA in estrogen receptor positive breast cancer patients"}]},{"@id":"https://cir.nii.ac.jp/crid/1360567186772763264","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Prevalence of ESR1 E380Q mutation in tumor tissue and plasma from Japanese breast cancer patients"}]},{"@id":"https://cir.nii.ac.jp/crid/1360574094619297664","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"The search for ESR1 mutations in breast cancer"}]},{"@id":"https://cir.nii.ac.jp/crid/1360574095358772224","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing"}]},{"@id":"https://cir.nii.ac.jp/crid/1360576118726136320","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"The Impact of Immunofunctional Phenotyping on the Malfunction of the Cancer Immunity Cycle in Breast Cancer"}]},{"@id":"https://cir.nii.ac.jp/crid/1360855570549055872","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Digital PCR"}]},{"@id":"https://cir.nii.ac.jp/crid/1361137046236520192","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer"}]},{"@id":"https://cir.nii.ac.jp/crid/1361418519286289792","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Plasma <i>ESR1</i> Mutations and the Treatment of Estrogen Receptor–Positive Advanced Breast Cancer"}]},{"@id":"https://cir.nii.ac.jp/crid/1361981471472955776","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Activating ESR1 mutations in hormone-resistant metastatic breast cancer"}]},{"@id":"https://cir.nii.ac.jp/crid/1362262945023073536","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Noninvasive Identification and Monitoring of Cancer Mutations by Targeted Deep Sequencing of Plasma DNA"}]},{"@id":"https://cir.nii.ac.jp/crid/1362262946178076416","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Absolute quantification by droplet digital PCR versus analog real-time PCR"}]},{"@id":"https://cir.nii.ac.jp/crid/1362825893487792000","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Endocrine-Therapy-Resistant ESR1 Variants Revealed by Genomic Characterization of Breast-Cancer-Derived Xenografts"}]},{"@id":"https://cir.nii.ac.jp/crid/1362825895271954560","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Clinical significance of androgen receptor and its phosphorylated form in breast cancer"}]},{"@id":"https://cir.nii.ac.jp/crid/1362825895531434240","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Analysis of\n            <i>ESR1</i>\n            mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer"}]},{"@id":"https://cir.nii.ac.jp/crid/1363107369962667776","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Circulating tumor cells and circulating tumor DNA for precision medicine: dream or reality?"}]},{"@id":"https://cir.nii.ac.jp/crid/1363388843436134144","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Prevalence of <i>ESR1</i> Mutations in Cell-Free DNA and Outcomes in Metastatic Breast Cancer"}]},{"@id":"https://cir.nii.ac.jp/crid/1363388843709236736","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer"}]},{"@id":"https://cir.nii.ac.jp/crid/1363388844480989056","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"D538G Mutation in Estrogen Receptor-α: A Novel Mechanism for Acquired Endocrine Resistance in Breast Cancer"}]},{"@id":"https://cir.nii.ac.jp/crid/1363670321200760704","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"BEAMing up for detection and quantification of rare sequence variants"}]},{"@id":"https://cir.nii.ac.jp/crid/1364233268534555904","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Pyrophosphorolysis-Activated Polymerization (PAP): Application to Allele-Specific Amplification"}]},{"@id":"https://cir.nii.ac.jp/crid/1364233271081004416","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Emergence of Constitutively Active Estrogen Receptor-α Mutations in Pretreated Advanced Estrogen Receptor–Positive Breast Cancer"}]},{"@id":"https://cir.nii.ac.jp/crid/1370849942261133952","@type":"Product","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"ESR1 mutations in circulating plasma tumor DNA from metastatic breast cancer patients"}]},{"@id":"https://cir.nii.ac.jp/crid/1370849942261134086","@type":"Product","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Inhibition of estrogen receptor action by a naturally occurring variant in human breast tumors"}]},{"@id":"https://cir.nii.ac.jp/crid/1370849942261134216","@type":"Product","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Constitutively active human estrogen receptors containing amino acid substitutions for tyrosine 537 in the receptor protein"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1016/j.tranon.2017.07.004"},{"@type":"KAKEN","@value":"PRODUCT-21861689"},{"@type":"KAKEN","@value":"PRODUCT-21552652"},{"@type":"OPENAIRE","@value":"doi_dedup___::3542e1691dd7af6d890661f89c459c70"},{"@type":"CROSSREF","@value":"10.1007/978-1-4939-8973-7_8_references_DOI_4wVFGlWnB4Wmt57bsyIk9uau8wL"},{"@type":"CROSSREF","@value":"10.1186/s12885-017-3779-2_references_DOI_4wVFGlWnB4Wmt57bsyIk9uau8wL"},{"@type":"CROSSREF","@value":"10.3390/cancers13010110_references_DOI_4wVFGlWnB4Wmt57bsyIk9uau8wL"}]}